AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2024
Mar 15, 2024
31523_dirs_2024-03-15_c6d1c1da-795f-4a2c-8b71-7efb2165e0e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2024-01-09
Reporting Person: Crowley John F (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-09 | Common Stock | A | 57620 | $0.0 | Acquired | 995492 | Direct |
| 2024-01-09 | Common Stock | F | 36865 | $13.65 | Disposed | 958627 | Direct |
| 2024-01-10 | Common Stock | S | 31614 | $13.6475 | Disposed | 927013 | Direct |
Footnotes
F1: Granted for the achievement of the 2021 PRSU TSR goal as determined by the Compensation and Leadership Development Committee of the Board of Directors.
F2: On January 11, 2024, the reporting person filed a Form 4 which inadvertently excluded the acquisition of shares granted for the achievement of the TSR portion of the 2021 PRSU award and inadvertently reported incorrect holdings following both shares being withheld for taxes and a sale transaction. This Form 4 amendment reflects these transactions and the reporting person's holdings following these transactions correctly.
F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.48 to $13.96 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.